As 2025 ends, delve into some biotech feel-good stories where the right treatment meets the right patient, almost feeling ...

BIO-Europe Startup Spotlight returns to Lisbon in March 2026, showcasing Europe’s top early-stage biotech pitches to industry leaders.

Asking whether China is the future of the biotech industry might seem counterintuitive, considering the current biotech geopolitical context. If you haven’t followed this series of events, a ...

Last year, we took a look at the biotech trends that we thought would shape 2024. Now, as we enter the new year, the biotech industry is continuing to evolve at a rapid pace, and 2025 is shaping up to ...

Starting a biotech company is a daunting journey filled with both challenges and opportunities. Unlike many other industries, the path from idea to market in biotech can be particularly long. To build ...

Aiolos Bio has emerged as a significant player in the biopharmaceutical industry, with a focus on developing treatments for respiratory and inflammatory diseases. The company’s launch in 2023, backed ...

The OECD recently published an update on key biotechnology indicators, an opportunity for us to delve into the top-performing countries in the field. With the highest number of active biotech ...

Discovered in the late 1990s, Small interfering RNA (siRNA) is a class of double-stranded RNA molecules, involved in the RNA interference (RNAi) pathway, where it mediates the silencing of specific ...

When Turnstone Biologics was founded, its team had high hopes for the California-based biotech to “lead the fight against solid tumors.” At first, it was keen on developing oncolytic viruses, which ...

As one of the top Ivy League schools in the U.S., Harvard University’s academic prestige is recognized all over the world. Among its many graduate programs, the university offers students the ...

Once a booming field, bustling with innovation and money driving that innovation, the cell and gene therapy sector is now struggling to fuel therapeutic growth to bring medicines to patients. It doesn ...

If you were to look back just a little over two years ago to the start of 2021, then putting money into a biotech company seemed like a pretty safe bet. After all, the COVID-19 pandemic had shined a ...